[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-370801-105":59,"doc-detail-370801-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","role-of-metabolomic-changes-in-diagnosis-and-assessment-of-treatment-response-in-acute-myeloid-leukemia","Role of Metabolomic Changes in Diagnosis and Assessment of Treatment Response in Acute Myeloid Leukemia","","Acute myeloid leukemia (AML) is an aggressive malignancy with variable outcomes, driving the need for more accurate diagnostic and prognostic biomarkers. A cross-sectional study compared metabolomic profiles between 56 AML patients sampled before and after chemotherapy and 56 age- and sex-matched healthy controls. Whole blood and serum metabolomics were measured using a Bruker 600 MHz NMR spectrometer, revealing significant metabolic alterations between patients and controls and between remission and non-remission groups. Lipid, amino acid metabolism, and glycolysis pathways were disrupted (p \u003C 0.05). Acetate, creatine, and lactate showed strong diagnostic performance (AUC = 0.98), while citrate, glutamate, and choline supported prognostic discrimination (AUC = 0.89) (p \u003C 0.05), indicating value for personalized diagnostic and therapeutic strategies.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/role-of-metabolomic-changes-in-diagnosis-and-assessment-of-treatment-response-in-acute-myeloid-leukemia/370801/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/role-of-metabolomic-changes-in-diagnosis-and-assessment-of-treatment-response-in-acute-myeloid-leukemia/370801.png","ImageObject",300,407,{"name":92,"@type":93},"Dipper","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-24","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What was the main objective of the study on AML metabolomics?","Question",{"text":112,"@type":113},"To compare metabolomic profiles between AML patients and healthy controls, evaluate diagnostic accuracy of metabolites, and assess prognostic significance at the first bone marrow follow-up.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were metabolomic profiles measured in the study?",{"text":117,"@type":113},"Whole blood and serum samples were analyzed using a Bruker 600 MHz NMR spectrometer.",{"name":119,"@type":110,"acceptedAnswer":120},"Which metabolite panels showed the strongest diagnostic and prognostic value?",{"text":121,"@type":113},"Acetate, creatine, and lactate provided strong diagnostic potential (AUC = 0.98), while citrate, glutamate, and choline demonstrated prognostic utility (AUC = 0.89) for distinguishing remission from non-remission.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},370801,1790444221,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},1374404997633,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","[www. nature.com/scientificreports](www. nature.com/scientificreports)  \nOPEN  \nRole of metabolomic changes in diagnosis and assessment of treatment response in acute myeloid leukemia  \nShabbir Hussain1􀀍, Farhat Bano1􀀍, Muhammad Ikram Ullah3, Rahat Abdul Rehman4, Kausar Bano5 & Muhammad Asif Naveed2  \nAcute Myeloid Leukemia (AML) is an aggressive cancer characterized by the rapid proliferation of abnormal myeloid cells. Despite advancements in treatment, patient outcomes remain variable, underscoring the need for more accurate diagnostic and prognostic tools. Metabolomics has gained attention for its potential to offer new insights into disease mechanisms and progression. This study aimed to compare metabolomic profiles between AML patients and normal controls, determine the diagnostic accuracy of different metabolites inAML patients, assess the diagnostic accuracy of specific metabolites inAML patients, and evaluate the prognostic significance of these metabolites at the first bone marrow follow-up. The cross-sectional study included 56 AML patients (sampled before and after chemotherapy) and 56 age-and sex-matched healthy controls. Whole blood and serum samples were collected from all participants after obtaining informed consent. Metabolomic analysis was performed using a Bruker 600 MHz NMR spectrometer. Results revealed significant metabolic alterations between AML patients and healthy controls, as well as in remission and non-remission groups. Key disrupted pathways included lipid metabolism, amino acid metabolism, and glycolysis (p \u003C 0.05) . Metabolite panels such as acetate, creatine, and lactate demonstrated strong diagnostic potential (AUC = 0.98), while citrate, glutamate, and choline panels (AUC = 0.89) showed prognostic utility in distinguishing patients from controls and remission from non-remission groups, respectively (p \u003C 0.05). The study highlights significant metabolomic alterations inAML patients, marked by disruptions in lipid, energy, and amino acid metabolism, elevated glucose levels, and enhanced diagnostic and prognostic capabilities. These findings support the development of personalized diagnostic and therapeutic strategies.  \nKeywords Acute myeloid leukemia, NMR, Metabolomics, Diagnostic biomarkers, Prognostic biomarkers  \nAcute myeloid leukemia (AML) is a rare but lethal malignancy of precursors of myeloid stem cell lineage, which includes platelets, red blood cells (RBCs), and white blood cells (WBCs) but excludes B and T cells, leading to clonal proliferation and overproduction of neoplastic myeloid stem cells1,2. AML has an overall five-year survival rate of approximately 25% due to its aggressive clinical course3,4. Adults with AML typically experience a range of symptoms, including exhaustion, bruising or bleeding, fever, and infections, which are indicators of failing bone marrow5. AML is more prevalent in adults than in children. In contrast, acute lymphoblastic leukemia (ALL) is the most common form of leukemia in children and the second most frequent type in adults6. Approximately half of the leukemia cases are acute, with ALL being the most common cancer in children. In contrast, the incidence of AML is around 3 to 8 cases per 100,000 people annually worldwide, with more than 80% of these cases occurring in adults7,8. The survival rate for leukemia over five years is 54% . However, forchildren under 15, the five-year relative survival rate is 89% for ALL and 60% for AML7.  \n1Department of Biochemistry, University of Health Sciences, Lahore 54600, Pakistan. 2Department of Hematology, University of Health Sciences, Lahore 54600, Pakistan. 3Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, 72388 Sakaka, Aljouf, Saudi Arabia. 4Department of Forensic Medicine and Medical Jurisprudence, University of Health Sciences, Lahore 54600, Pakistan. 5Oncology Department, Jinnah Hospital, Allama Iqbal Medical College, Lahore 54600, Pakistan. 􀀍 email: [ashas740@yahoo.com](ash","cbCaieQwbHva93Ar","https://ap.wps.com/l/cbCaieQwbHva93Ar","pdf",2395627,15,"English","# Background\n## Clinical challenges in AML diagnosis and prognosis\n## Role of metabolomics and NMR\n# Study Design\n## Participants and sampling\n## Metabolomic analysis method\n# Results\n## Metabolic differences across groups\n## Altered pathways\n## Diagnostic and prognostic metabolite panels\n# Implications","[{\"question\":\"What was the main objective of the study on AML metabolomics?\",\"answer\":\"To compare metabolomic profiles between AML patients and healthy controls, evaluate diagnostic accuracy of metabolites, and assess prognostic significance at the first bone marrow follow-up.\"},{\"question\":\"How were metabolomic profiles measured in the study?\",\"answer\":\"Whole blood and serum samples were analyzed using a Bruker 600 MHz NMR spectrometer.\"},{\"question\":\"Which metabolite panels showed the strongest diagnostic and prognostic value?\",\"answer\":\"Acetate, creatine, and lactate provided strong diagnostic potential (AUC = 0.98), while citrate, glutamate, and choline demonstrated prognostic utility (AUC = 0.89) for distinguishing remission from non-remission.\"}]","Role of Metabolomic Changes in Diagnosis and Assessment of Treatment Response in Acute Myeloid Leukemia | PDF",1790190406,38,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/80c76e5d31cfd6b4c8687767f4333794.webp",983,1291,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f2960ebe1d9e88b5f264aa7b76b17184.webp",982,1290,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c1ce76ed4a92da671f98e4bdf4b0483d.webp",981,1289,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/89889e193d10e4285fff560adab1819b.webp",980,1287]